1. Home
  2. VIGL vs LSBK Comparison

VIGL vs LSBK Comparison

Compare VIGL & LSBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • LSBK
  • Stock Information
  • Founded
  • VIGL 2020
  • LSBK 1891
  • Country
  • VIGL United States
  • LSBK United States
  • Employees
  • VIGL N/A
  • LSBK N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • LSBK Savings Institutions
  • Sector
  • VIGL Health Care
  • LSBK Finance
  • Exchange
  • VIGL Nasdaq
  • LSBK Nasdaq
  • Market Cap
  • VIGL 89.3M
  • LSBK 91.1M
  • IPO Year
  • VIGL 2022
  • LSBK 2006
  • Fundamental
  • Price
  • VIGL $2.58
  • LSBK $15.82
  • Analyst Decision
  • VIGL Strong Buy
  • LSBK
  • Analyst Count
  • VIGL 5
  • LSBK 0
  • Target Price
  • VIGL $21.00
  • LSBK N/A
  • AVG Volume (30 Days)
  • VIGL 2.7M
  • LSBK 3.1K
  • Earning Date
  • VIGL 03-25-2025
  • LSBK 01-24-2025
  • Dividend Yield
  • VIGL N/A
  • LSBK 4.63%
  • EPS Growth
  • VIGL N/A
  • LSBK 7.32
  • EPS
  • VIGL N/A
  • LSBK 0.88
  • Revenue
  • VIGL N/A
  • LSBK $25,846,000.00
  • Revenue This Year
  • VIGL N/A
  • LSBK N/A
  • Revenue Next Year
  • VIGL N/A
  • LSBK N/A
  • P/E Ratio
  • VIGL N/A
  • LSBK $17.67
  • Revenue Growth
  • VIGL N/A
  • LSBK N/A
  • 52 Week Low
  • VIGL $1.49
  • LSBK $10.30
  • 52 Week High
  • VIGL $6.06
  • LSBK $15.98
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 66.89
  • LSBK 66.16
  • Support Level
  • VIGL $2.53
  • LSBK $15.53
  • Resistance Level
  • VIGL $2.88
  • LSBK $15.78
  • Average True Range (ATR)
  • VIGL 0.30
  • LSBK 0.33
  • MACD
  • VIGL 0.06
  • LSBK 0.16
  • Stochastic Oscillator
  • VIGL 70.98
  • LSBK 83.65

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About LSBK Lake Shore Bancorp Inc.

Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.

Share on Social Networks: